Skip to content

Research on Establishing a bleeding Risk Prediction Model for Pregnant and Postpartum Women with VTE Based on interpretable machine Learning Algorithms

Research on Establishing a bleeding Risk Prediction Model for Pregnant and Postpartum Women with VTE Based on interpretable machine Learning Algorithms

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500108590
Enrollment
Unknown
Registered
2025-09-02
Start date
2025-09-10
Completion date
Unknown
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Venous thromboembolism

Interventions

Sponsors

Department of Pharmacy, Fujian Maternity and Child Health Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Healthy Pregnant Women: 1. Age between 18 - 45 years; 2. Singleton pregnancy; 3. No pregnancy complications, such as ectopic pregnancy, placenta previa, placental abruption, intrahepatic cholestasis during pregnancy, acute fatty liver disease during pregnancy, etc.; 4. Volunteer to participate in the study and sign the informed consent form. Non-pregnant healthy women: 1. Age between 18 - 45 years; 2. Volunteer to participate in the study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: Healthy Pregnant Women: 1. High blood pressure, diabetes, thyroid disease, etc.; 2. Autoimmune diseases: such as systemic lupus erythematosus, rheumatic and rheumatoid arthritis, etc 3. Malignant tumors: such as breast cancer, ovarian cancer, lung cancer, etc 4. History of severe infection, severe burns, major surgery, etc. within three months before the start of the study; Severe infection: Sequential Organ Failure Assessment (SOFA) score increases by >=2 points from baseline level, diagnosed as purulent meningitis; bronchopneumonia; infective endocarditis; septic shock, etc.; Severe burns: total basic surface area (TBSA) >=30%, or third-degree burns >=10%, or less than 30% of the total area, but the whole body is severe or has shock, compound injuries, or moderate to severe inhalation injuries; Surgery: Performed difficult surgery with high risk of grade 3 or 4, involving important organs (such as heart, liver, brain, large blood vessels); organ transplantation, etc.; 5. Smoking, drinking alcohol the day before blood collection; 6. Are using antiplatelet or anticoagulant drugs such as aspirin, heparin, warfarin, direct oral anticoagulants, etc.; 7. Heart diseases such as heart failure and arrhythmia; Severe liver and kidney insufficiency; 8. History of coagulation disorders, previously diagnosed with hereditary or acquired coagulation disorders, such as hemophilia, von Willebrand disease, thrombocytopenia, etc.; 9. Current pregnancy is IVF/embryo transfer; 10. Diagnosis of preeclampsia in the course of pregnancy. Non-pregnant healthy women: 1. High blood pressure, diabetes, thyroid disease, etc.; 2. Autoimmune diseases: such as systemic lupus erythematosus, rheumatoid and rheumatoid arthritis, etc.; 3. Malignant tumors: such as breast cancer, ovarian cancer, lung cancer, etc.; 4. History of severe infection, severe burns, major surgery, etc. within three months before the start of the study; Severe infection: Sequential Organ Failure Assessment (SOFA) score increases by >=2 points from baseline level, diagnosed as purulent meningitis; bronchopneumonia; infective endocarditis; septic shock, etc.; Severe burns: total basic surface area (TBSA) >=30%, or third-degree burns >=10%, or less than 30% of the total area, but the whole body is severe or has shock, compound injuries, or moderate to severe inhalation injuries; Surgery: Performed difficult surgery with high risk of grade 3 or 4, involving important organs (such as heart, liver, brain, large blood vessels); organ transplantation, etc.; 5. Smoking, drinking alcohol the day before blood collection; 6. Are using antiplatelet or anticoagulant drugs such as aspirin, heparin, warfarin, direct oral anticoagulants, etc.; 7. Heart diseases such as heart failure and arrhythmia; Severe liver and kidney insufficiency; 8. History of coagulation disorders, previously diagnosed with hereditary or acquired coagulation disorders, such as hemophilia, von Willebrand disease, thrombocytopenia, etc.

Design outcomes

Primary

MeasureTime frame
Coagulation-related indicators;

Countries

China

Contacts

Public ContactZhang Jinhua

Department of Pharmacy, Fujian Maternity and Child Health Hospital

pollyzhang2006@126.com+86 133 0691 2381

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026